natgillin/translations-raw huggingface dataset:
Desloratadine Teva is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with: - allergic rhinitis (see section 5.1) - urticaria (see section 5.1) 
Desloratadin Teva je indiciran u odraslih i adolescenata u dobi od 12 ili više godina za ublažavanje simptoma povezanih s: - alergijskim rinitisom (vidjeti dio 5.1), - urtikarijom (vidjeti dio 5.1).
OPA/Alu/PVC - Aluminium perforated unit dose blisters. 
OPA/Alu/PVC-aluminij perforirani blisteri djeljivi na jedinične doze.
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, United Kingdom or 
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, Ujedinjeno Kraljevstvo ili
- The other ingredients are microcrystalline cellulose, pregelatinised maize starch, talc, silica colloidal anhydrous, lactose monohydrate, hypromellose, titanium dioxide (E171), macrogol 400, indigo carmine (E132), shellac and propylene glycol. 
- Pomoćne tvari su: mikrokristalična celuloza, prethodno geliran kukuruzni škrob, talk, koloidni bezvodni silicijev dioksid, laktoza hidrat, hipromeloza, titanijev dioksid (E171), makrogol 400, indigo carmine (E132), šelak i propilenglikol.
Merckle GmbH Ludwig-Merckle-Strasse 3 D-89143 Blaubeuren Germany 
Merckle GmbH Ludwig-Merckle-Strasse 3 D-89143 Blaubeuren
Pack of 50 x 1 film-coated tablet (unit dose). 
Pakiranje od 50 x 1 filmom obložena tableta (jedinična doza).
In both studies, changes in exposure (AUC and Cmax) of desloratadine and 3-hydroxydesloratadine were not clinically relevant. 
U oba ispitivanja promjene u izloženosti (AUC i Cmax) desloratadinu i 3
Desloratadine Teva is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). 
Desloratadin Teva se također koristi za ublažavanje simptoma povezanih s urtikarijom (promjene na koži uslijed alergije).
As a precautionary measure, it is preferable to avoid the use of Desloratadine Teva 5 mg film-coated tablets during pregnancy. 
Kao mjera opreza, preporučuje se izbjegavati primjenu lijeka Desloratadin Teva 5 mg filmom obložene tablete tijekom trudnoće.
Adults During the marketing of Desloratadine Teva, the following side effects were reported as: 
Odrasli Nakon stavljanja u promet lijeka Desloratadin Teva, sljedeće su nuspojave prijavljene kao:
Blue, round, biconvex film-coated tablet - printed in with ink: “D5” on one side and plain on the other. 
Plava, okrugla, bikonveksna filmom obložena tableta - s otisnutom oznakom "D5" na jednoj strani te bez oznaka na drugoj strani tablete.
Not known: frequency cannot be estimated from the available data 
Nepoznata učestalost: ne može se procijeniti iz dostupnih podataka ● usporen rad srca
Pharmacotherapeutic group: antihistamines - H1 antagonist, ATC code: R06A X27 
Farmakoterapijska skupina: Ostali antihistaminici za sustavnu primjenu, ATK oznaka: R06AX27 Mehanizam djelovanja
Elevations of liver enzymes, increased bilirubin, hepatitis 
povišeni bilirubin, hepatitis Žutica
Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria) Asthenia 
Reakcije preosjetljivosti (poput anafilaksije, angioedema, dispneje, pruritusa, osipa i urtikarije)
What Desloratadine Teva is and what it is used for What you need to know before you take Desloratadine Teva How to take Desloratadine Teva Possible side effects 
Što je Desloratadin Teva i za što se koristi Što morate znati prije nego počnete uzimati Desloratadin Teva Kako uzimati Desloratadin Teva
Desloratadine Teva is an antiallergy medicine that does not make you drowsy. 
Desloratadin Teva je lijek protiv alergije koji ne izaziva pospanost.
As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as nonresponsive to antihistamines was excluded. 
Kao i kod drugih ispitivanja antihistaminika kod kronične idiopatske urtikarije, manji broj pacijenata, kod kojih je utvrđeno da ne reagiraju na antihistaminike, bio je isključen iz ispitivanja.
Desloratadine has no or negligible influence on the ability to drive and use machines based on clinical trials. 
Desloratadin ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
In a clinical pharmacology trial, desloratadine tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). 
U kliničkom farmakološkom ispitivanju, uzimanje desloratadin tableta s alkoholom nije pojačalo štetne učinke alkohola na ponašanje (vidjeti dio 5.1).
Titanium dioxide (E171) Propylene glycol 
Tinta za označavanje šelak titanijev dioksid (E171) propilenglikol
Desloratadine is the primary active metabolite of loratadine. 
5.3 Neklinički podaci o sigurnosti primjene Desloratadin je primarni aktivni metabolit loratadina.
50 x 1 film-coated tablet (unit dose) 60 film-coated tablets 
50 x 1 filmom obložena tableta (jedinična doza) 60 filmom obloženih tableta
The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to 
Učestalost pojavljivanja definirana je kao: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i
Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea 
Bol u abdomenu, mučnina, povraćanje, dispepsija, proljev
Sími: +354 522 2900 
Alvogen ehf. Sími: +354 522 2900
Desloratadine Teva contains lactose. 
Desloratadin Teva sadrži laktozu.
Ludwig-Merckle-Strasse 3, D-89143 Blaubeuren Germany 
Merckle GmbH Ludwig-Merckle-Strasse 3, D-89143 Blaubeuren
- The active substance is 5 mg desloratadine. 
- Djelatna tvar je 5 mg desloratadina.
EU/1/11/732/013 50 x 1 film-coated tablet (unit dose) EU/1/11/732/014 105 film-coated tablets 
EU/1/11/732/013 50 x 1 filmom obložena tableta (jedinična doza) EU/1/11/732/013 105 filmom obloženih tableta
In another study, grapefruit juice had no effect on the disposition of desloratadine. 
sok od grejpa nije utjecao na raspoloživost desloratadina.
Adverse reactions seen with desloratadine 
Nuspojave opažene uz Desloratadin Teva
Keep this medicine out of the sight and reach of children. 
Kako čuvati Desloratadin Teva Ovaj lijek čuvajte izvan pogleda i dohvata djece.
If you stop taking Desloratadine Teva 
Ako prestanete uzimati Desloratadin Teva
The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single-dose study and one multiple dose study. 
Bolesnici s oštećenjem funkcije bubrega Farmakokinetika desloratadina u bolesnika s kroničnom insuficijencijom bubrega bila je uspoređivana s onom u zdravih ispitanika u jednom ispitivanju jednokratnih doza te u ispitivanju višekratnih doza.
Package leaflet: Information for the patient Desloratadine Teva 5 mg film-coated tablets 
Uputa o lijeku: Informacija za bolesnika Desloratadin Teva 5 mg filmom obložene tablete desloratadin
What you need to know before you take Desloratadine Teva Do not take Desloratadine Teva 
Što morate znati prije nego počnete uzimati Desloratadin Teva
If you forget to take Desloratadine Teva 
Ako ste zaboravili uzeti Desloratadin Teva
Hungary or 
Mađarska ili
● stomach ache 
● upala jetre
Desloratadine Teva 5 mg film-coated tablets 
Desloratadin Teva 5 mg filmom obložene tablete
Tablet coating Lactose monohydrate Hypromellose Titanium dioxide (E171) Macrogol 400 
Ovojnica tablete laktoza hidrat hipromeloza titanijev dioksid (E171) makrogol 400 indigo carmine (E132)
Pharmachemie B.V. Swensweg 5, 2031 GA Haarlem, The Netherlands or 
Swensweg 5, 2031 GA Haarlem, Nizozemska ili
How Desloratadine Teva works 
Kako djeluje Desloratadin Teva
Tel: +39 02 8917981 
Teva Italia S.r.l. Tel: +39 02 8917981
How to take Desloratadine Teva 
Kako uzimati Desloratadin Teva
● restlessness with increased 
● nemir s pojačanim
Desloratadine Teva contains lactose 
Desloratadin Teva sadrži laktozu
Desloratadine Teva 5 mg film-coated tablets Desloratadine 
Desloratadin Teva 5 mg filmom obložene tablete desloratadin
Weight increased 
● povećana tjelesna težina
21 film-coated tablets 
21 filmom obloženih tableta
105 film-coated tablets 
105 filmom obloženih tableta
Marketing Authorisation Holder and Manufacturer 
Nositelj odobrenja za stavljanje gotovog lijeka u promet i proizvođač Nositelj odobrenja
However, if you take more Desloratadine Teva than you were told to, tell your doctor, pharmacist or nurse immediately. 
Vam je propisano, odmah o tome obavijestite svog liječnika, ljekarnika ili medicinsku sestru.
Microcrystalline cellulose Pregelatinised maize starch Talc 
Jezgra tablete celuloza, mikrokristalična kukuruzni škrob, prethodno geliran talk silicijev dioksid, koloidni, bezvodni
EU/1/11/732/011 90 film-coated tablets 
EU/1/11/732/011 90 filmom obloženih tableta
EU/1/11/732/012 100 film-coated tablets 
EU/1/11/732/012 100 filmom obloženih tableta
When Desloratadine Teva should be used 
Kada treba uzimati Desloratadin Teva
EU/1/11/732/006 28 film-coated tablets 
EU/1/11/732/006 28 filmom obloženih tableta
Taking Desloratadine Teva is not recommended if you are pregnant or nursing a baby. 
Ako ste trudni ili dojite, nije preporučljivo uzimati Desloratadin Teva.
EU/1/11/732/010 60 film-coated tablets 
EU/1/11/732/010 60 filmom obloženih tableta
EU/1/11/732/007 30 film-coated tablets 
EU/1/11/732/007 30 filmom obloženih tableta
EU/1/11/732/008 40 film-coated tablets 
EU/1/11/732/008 40 filmom obloženih tableta
EU/1/11/732/005 21 film-coated tablets 
EU/1/11/732/005 21 filmom obložena tableta
● feeling sick (nausea) 
● želučane tegobe ● proljev
EU/1/11/732/009 50 film-coated tablets 
EU/1/11/732/009 50 filmom obloženih tableta
EU/1/11/732/004 20 film-coated tablets 
EU/1/11/732/004 20 filmom obloženih tableta
EU/1/11/732/002 10 film-coated tablets 
EU/1/11/732/002 10 filmom obloženih tableta
EU/1/11/732/003 14 film-coated tablets 
EU/1/11/732/003 14 filmom obloženih tableta
Desloratadine 
Astenija
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION • Periodic Safety Update Reports 
OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
EU/1/11/732/001 7 film-coated tablets 
EU/1/11/732/001 7 filmom obloženih tableta
Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43(0)1 97 007 0 
Österreich ratiopharm Arzneimittel Vertriebs-GmbH
The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. 
(približno 27 sati) i s učestalosti doziranja jednom dnevno.
Patients must also not use oral contraceptives. 
Bolesnice ne smiju koristiti oralne kontraceptive.
It is available as a solution for injection. 
Dostupan je kao suspenzija za injekciju.
This is a subgroup of severely affected patients with a high unmet medical need. 
Ovo je podgrupa ozbiljno zahvaćenih bolesnika s visokom nezadovoljenom medicinskom potrebom.
Glybera alipogene tiparvovec 
Glybera alipogen tiparvovek
The amount of the medicine to inject and the number of injections depend on the patient's weight. 
Količina lijeka koja se ubrizgava i broj injekcija ovise o tjelesnoj težini bolesnika.
Glybera has been authorised under ‘exceptional circumstances' as it has not been possible to obtain complete information about the medicine, because of the rarity of the disease. 
Lijek Glybera odobren je pod „iznimnim okolnostima” budući da nije bilo moguće dobiti potpune informacije o lijeku uslijed rijetke prirode bolesti.
The medicine will only be supplied to doctors who have received the appropriate educational materials and will only be used to treat patients participating in the registry. 
Lijek će se isporučivati samo liječnicima koji su primili odgovarajuće edukacijske materijale te će se primjenjivati samo za liječenje bolesnika upisanih u registru.
The European Commission granted a marketing authorisation valid throughout the European Union for Glybera on 25 October 2012. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Glybera na snazi u Europskoj uniji od 25. listopada 2012.
There was also a reduction in the number of pancreatitis attacks in some patients, as well as fewer hospital admissions and stays in intensive care units. 
Bilo je prisutno i smanjenje broja napadaja pankreatitisa u pojedinih bolesnika kao i manji broj primitaka u bolnicu i boravaka na jedinicama intenzivne skrbi.
The modified viral material used in Glybera does not cause infections and cannot make copies of itself. 
Modificirani virusni materijal koji se koristi u lijeku Glybera ne uzrokuje infekcije i ne može stvarati vlastite kopije.
One patient was diagnosed with pulmonary embolism (clots in blood vessels supplying the lungs) seven weeks after treatment. 
Jednom bolesniku dijagnosticiran je pulmonalni embolizam (ugrušci u krvnim žilama koje opskrbljuju pluća) sedam tjedana nakon terapije.
The majority of patients who received Glybera also received immunosuppressive treatment. 
Većina bolesnika koja je primila lijek Glybera primila je također imunosupresivnu terapiju.
Patients will also be provided with a patient alert card. 
Bolesnici će također dobiti karticu s upozorenjima za bolesnike.
Glybera must not be used in patients with immunodeficiency (weakened immunity), increased risk of bleeding and muscle disease. 
Glybera se ne smije koristiti u bolesnika s imunodeficijencijom (oslabljenim imunitetom), povišenim rizikom od krvarenja i mišićnom bolesti.
Anticoagulant medicines, which can increase bleeding, must not be used from the week before Glybera treatment to one day after. 
Antikoagulacijski lijekovi, koji mogu povećati krvarenje, ne smiju se koristiti tjedan dana prije primjene terapije lijekom Glybera do jednog dana nakon te terapije.
The CHMP therefore recommended that the medicine be granted marketing authorisation. 
CHMP je stoga preporučio da se za lijek izda odobrenje za stavljanje u promet.
This is a summary of the European public assessment report (EPAR) for Glybera. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Glybera.
The full EPAR for Glybera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Glybera nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Other common side effects reported include headache, tiredness, hyperthermia (high body temperature), contusion (bruising) and increased levels of the enzyme creatine kinase in the blood (a measure of damage to muscle tissue). 
Druge prijavljene česte nuspojave uključivale su glavobolju, umor, hipertermiju (visoku tjelesnu temperaturu), kontuzije (masnice) i povišene koncentracije enzima kreatin kinaze u krvi (mjerilo oštećenja mišićnog tkiva).
Glybera is a type of advanced therapy medicine called a ‘gene therapy product'. 
Glybera je vrsta lijeka za naprednu terapiju koji se naziva „lijek za gensku terapiju”.
Due to the multiple injections required, it is advisable to give it with a spinal or regional anaesthetic (medicines which numb certain parts of the body to block pain). 
Zbog potrebe za višestrukim injekcijama, savjetuje se davanje injekcija zajedno s anestezijom u kralježnicu ili lokalnom anestezijom (lijekovima koji otupljuju određene dijelove tijela kako bi se blokirala bol).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glybera. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Glybera.
What measures are being taken to ensure the safe and effective use of Glybera? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Glybera?
For three days before Glybera treatment and for twelve weeks after, patients are given immunosuppressive treatment to reduce the reaction of the body's immune system against the medicine. 
Tri dana prije početka terapije lijekom Glybera i dvanaest tjedana nakon terapije bolesnici primaju imunosupresivnu terapiju kako bi se smanjila reakcija imunosnog sustava tijela na lijek.
The enzyme produced by these cells can then help to break down fats in the blood, reducing the number of pancreatitis attacks and the severity of the disease. 
Enzimi koje proizvedu te stanice mogu im pomoći pri razgradnji masnoća u krvi, smanjujući broj napadaja pankreatitisa i ozbiljnost bolesti.
The most common side effect reported with Glybera was pain in the legs following the injections, which occurred in a third of patients. 
Najčešća nuspojava prijavljena pri primjeni lijeka Glybera bila je bol u nogama nakon injekcija, što je nastupilo u trećine bolesnika.
The summary of the opinion of the Committee for Orphan Medicinal Products for Glybera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Sažetak mišljenja Odbora za lijekove za rijetke bolesti za lijek Glybera dostupan je na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
After careful consideration of all the evidence and the circumstances of the disease, including its extreme rarity, the CHMP concluded that the results from studies showed that the benefits of Glybera outweigh its risks in patients with severe or multiple pancreatitis attacks despite following a low-fat diet. 
Nakon pažljivog razmatranja svih dokaza i okolnosti bolesti, uključujući i izuzetno rijetku pojavu bolesti, CHMP je zaključio da rezultati ispitivanja potvrđuju kako koristi lijeka Glybera nadmašuju s njim povezane rizike u bolesnika s ozbiljnim ili višestrukim napadajima pankreatitisa usprkos prehrani s niskim sadržajem masnoća.
Under the terms of the authorisation, the company is required to provide further data on fat levels in the blood after meals and on the immune response to Glybera in new patients. 
Sukladno uvjetima pod kojima je izdano odobrenje, od tvrtke se traži da dostavi dodatne podatke o koncentracijama masnoće u krvi nakon obroka i o imunosnom odgovoru na lijek Glybera u novih bolesnika.
Other information about Glybera 
Ostale informacije o lijeku Glybera
The company will also provide data from a registry to monitor the outcome of patients treated with Glybera, and will add a step to the manufacturing of the product to improve the safety profile. 
Tvrtka će također dostaviti podatke iz registra kako bi se pratili rezultati u bolesnika liječenih lijekom Glybera, te će dodati korak u postupku proizvodnje lijeka kako bi se poboljšao sigurnosni profil.
In addition, the company has put in place a restricted access programme to ensure that Glybera is used appropriately when the diagnosis is confirmed. 
Nadalje, tvrtka je uspostavila program ograničenog pristupa kako bi osigurala da se lijek Glybera koristi na primjeren način nakon što je dijagnoza potvrđena.
When injected into the muscles, it corrects the lipoprotein lipase deficiency by enabling the muscle cells to produce the enzyme. 
Ako se ubrizgava u mišić, on otklanja deficijenciju lipoproteinske lipaze omogućujući mišićnim stanicama da proizvode enzim.
Because the number of patients with lipoprotein lipase deficiency is low, the disease is considered ‘rare', and Glybera was designated an ‘orphan medicine' (a medicine used in rare diseases) on 8 March 2004. 
Budući da je broj bolesnika s deficijencijom lipoproteinske lipaze nizak, ta se bolest smatra „rijetkom” te je lijek Glybera 08. ožujka 2004. uvršten u skupinu lijekova za rijetke bolesti.
The data showed a reduction in blood fat levels after meals in some patients. 
Podaci su pokazali smanjenje koncentracije masnoće u krvi nakon obroka u pojedinih bolesnika.
The company will also provide patients and healthcare professionals with educational materials, including information on how to administer Glybera and how to manage risks with the medicine. 
Tvrtka će također dostaviti bolesnicima i zdravstvenim djelatnicima edukacijske materijale, uključujući i informacije o načinu primjene lijeka Glybera, te načinu upravljanja rizicima pri primjeni lijeka.
For more information about treatment with Glybera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Glybera pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
Glybera is used to treat adults with lipoprotein lipase deficiency who have severe or multiple attacks of pancreatitis (inflammation of the pancreas) despite maintaining a low-fat diet. 
Glybera se koristi za liječenje odraslih osoba s deficijencijom lipoproteinske lipaze (LPLD) koji su imali ozbiljne ili višestruke napadaje pankreatitisa (upale gušterače) usprkos prehrani s niskim sadržajem masnoća.
Although there were data for only a small number of patients, the results indicate that Glybera would be of benefit to those patients with severe or multiple pancreatitis attacks. 
Iako postoje podaci samo za mali broj bolesnika, rezultati pokazuju da je lijek Glybera od koristi za bolesnike s ozbiljnim ili višekratnim napadajima pankreatitisa.
Patients with this disease need to be on a strict low-fat diet and are prone to recurring attacks of pancreatitis, which is a severe and life-threatening complication. 
Bolesnici s ovom bolesti trebaju biti na strogoj dijeti s niskim sadržajem masnoća, a skloni su ponovnim napadajima pankreatitisa, što je ozbiljna i po život opasna komplikacija.
Given the small number of patients treated, these side effects do not provide a complete picture of the frequency and nature of the side effects of Glybera. 
Uzimajući u obzir mali broj liječenih bolesnika, ove nuspojave ne pružaju potpunu sliku o učestalosti i prirodi nuspojava lijeka Glybera.
A risk management plan has been developed to ensure that Glybera is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Glybera.
The main measures of effectiveness were the reduction in blood fat levels after meals and the reduction in the number of pancreatitis attacks. 
Glavno mjerilo djelotvornosti bilo je smanjenje koncentracije masnoće u krvi nakon obroka te smanjenje broja napadaja pankreatitisa.
Glybera is a medicine that contains the active substance alipogene tiparvovec. 
Glybera je lijek koji sadrži djelatnu tvar alipogen tiparvovek.
Lipoprotein lipase deficiency is a rare disease in which patients have a defect in the gene for lipoprotein lipase, an enzyme responsible for breaking down fats. 
Deficijencija lipoproteinske lipaze rijetka je bolest u slučaju koje bolesnici imaju nedostatak na genu za lipoprotein lipazu, enzim odgovoran za razgradnju masnoća.
The active substance in Glybera, alipogene tiparvovec, is derived from a virus that has been modified so it can carry the lipoprotein lipase gene into the body's cells. 
Djelatna tvar lijeka Glybera, alipogen tiparvovek, dobiva se iz virusa koji je modificiran tako da može prenositi gen lipoproteinske lipaze u tjelesne stanice.
What is the risk associated with Glybera? 
Koji su rizici povezani s lijekom Glybera?
Glybera should only be prescribed and given under the supervision of a doctor with expertise in treating lipoprotein lipase deficiency and in gene therapy. 
Lijek Glybera smije se propisivati i davati samo uz nadzor liječnika s iskustvom u liječenju deficijencije lipoproteinske lipaze i u genetskoj terapiji.
Glybera is only for patients whose disease has been confirmed by appropriate genetic testing and who have detectable levels of the lipoprotein lipase enzyme in their blood. 
Lijek Glybera namijenjen je samo za bolesnicima čija je bolest potvrđena odgovarajućim genetskim testiranjem i kod kojih je moguće detektirati razinu enzima lipoproteinske lipaze u krvi.
Glybera is given as a single treatment involving multiple injections into the muscles of the upper and lower legs. 
Glybera se primjenjuje kao jedna terapija koja uključuje višestruke injekcije u mišić bedra i potkoljenice.